Abstract 1485
Background
The Stupp protocol is the standard treatment of glioblastoma multiform (GBM). The non-dividing nature of normal brain cells is an opportunity to enhance the therapeutic ratio by combining radiation with inhibitors of replication-specific DNA repair pathways such PARP inhibitors as olaparib. PARP inhibition also increases cellular sensitivity to radiation and may be higher in tumor than in normal tissue. Progress in technical imaging and intensity-modulated-radiotherapy (IMRT) techniques provide new possibilities for sparing healthy tissues. We propose a phase 1/2a trial to assess the safety and efficacy of Olaparib combined with TMZ plus fractionated IMRT as a first line treatment in unresectable GBM patients (pts).
Trial design
Based on the Stupp phase 2 design, 2 treatment periods are considered. The radiotherapy (RT) period occurs after the last surgery: the pt receives IMRT, daily TMZ during IMRT and olaparib, given at the same dose until 4 weeks after the end of IMRT. For the maintenance (MT) period, the pt receives TMZ (days 1-5 every 28 days, for 6 cycles) plus olaparib (at the MT dose level up to disease progression or unacceptable toxicity). The phase 1 includes 2 consecutive dose escalations to separate both periods for DLT (Dose Limiting Toxicities) assessment. First 15 pts will receive olaparib only during the RT period to determine the MTD1 (Maximum-Tolerated Dose) among 7 dose levels, by assessing DLT on this period. Next 15 pts will all receive MTD1 during the RT period, and a new dose-escalation will determine MTD2 (≤MTD1) during the MT period, assessing DLT from the first 2 cycles. For phase 2a, IMRT and TMZ are given according to the Stupp protocol. Olaparib is given at the MTD1 during the RT period and at the MTD2 during the MT period. Brain disease is assessed using RANO criteria. The trial includes ancillary studies on tumor biopsies, spectro-MRI and neurocognitive and quality of life assessment. Up to 79 pts will be enrolled: 30 pts in the phase 1 and 49 pts in the phase 2a (Case&Morgan two-stage design). This trial (NCT03212742) is granted by the French Cancer Institute and Health Ministry (PHRC-K15-135) and Astra-Zeneca for olaparib provision. First pt was enrolled on Oct 2017.
Clinical trial identification
Legal entity responsible for the study
Comprehensive Cancer Centre François Baclesse.
Funding
AstraZeneca.
Editorial Acknowledgement
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2595 - Real-Life Utilization of Genomic testing for invasive Breast Cancer patients in Italy and France reduces Chemotherapy Recommendations
Presenter: Sandro Barni
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
2343 - Benefit of adjuvant chemotherapy in hormone receptor-positive, HER2-negative, invasive lobular carcinoma of the breast
Presenter: Alexandre De Nonneville
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
2990 - Baseline lymphocyte counts predict distant recurrence in early breast cancer
Presenter: Gun Min Kim
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
4532 - A propensity score analysis exploring the impact of the addition of adjuvant chemotherapy (aCT) to hormone therapy (aHT) in a multi-center series of resected luminal early stage pure Invasive Lobular Breast Carcinoma (ILC).
Presenter: Luisa Carbognin
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
2344 - Benefit of Adjuvant Systemic Therapies in HR+ HER2- pT1ab Node-Negative Breast Carcinomas
Presenter: Alexandre De Nonneville
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
3525 - Anti-proliferative effect of oral metronomic vinorelbine in PAM50 Luminal/HER2-negative early breast cancer (SOLTI-1501 VENTANA): an open-label, randomized, three-arm, multicenter, window-of-opportunity study
Presenter: Aleix Prat
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
3908 - Clinicopathologic significance of androgen receptor expression and discordant receptor status during progression in breast cancer
Presenter: Chan Heun Park
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
4075 - The outcomes of early breast cancers utilizing the Oncotype Dx Recurrence score (RS) instead of Clinico-pathological (CP) factors for prognostic risk assessment: A Single Institution Experience
Presenter: Adhar Alsayed
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
738 - Circulating tumor cells as a prognostic marker in non metastatic breast cancer patients.
Presenter: Summar Elmorshidy
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
3151 - Molecular subtyping of breast cancer by dedicated breast PET
Presenter: Satoshi Sueoka
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract